Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Autologous CD1c (BDCA-1)+ myDC |
| Synonyms | |
| Therapy Description |
Autologous CD1c (BDCA-1)+ MyDC are patient-derived myeloid dendritic cells expressing CD1c (BDCA-1), which potentially enhance antitumor immune response and inhibit tumor growth (PMID: 38212127). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Autologous CD1c (BDCA-1)+ myDC | Autologous CD1c (BDCA-1)+ MyDC are patient-derived myeloid dendritic cells expressing CD1c (BDCA-1), which potentially enhance antitumor immune response and inhibit tumor growth (PMID: 38212127). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03233152 | Phase Ib/II | Autologous CD1c (BDCA-1)+ myDC + Ipilimumab + Nivolumab Ipilimumab + Nivolumab Autologous CD1c (BDCA-1)+ myDC | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. (GlitIpNi) | Active, not recruiting | BEL | 0 |